JP2021502993A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021502993A5 JP2021502993A5 JP2020526612A JP2020526612A JP2021502993A5 JP 2021502993 A5 JP2021502993 A5 JP 2021502993A5 JP 2020526612 A JP2020526612 A JP 2020526612A JP 2020526612 A JP2020526612 A JP 2020526612A JP 2021502993 A5 JP2021502993 A5 JP 2021502993A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- compound according
- pharmaceutically acceptable
- carcinoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 44
- -1 dialkylamynylalkyl Chemical group 0.000 claims 31
- 206010028980 Neoplasm Diseases 0.000 claims 24
- 150000003839 salts Chemical class 0.000 claims 19
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 16
- 201000009030 Carcinoma Diseases 0.000 claims 16
- 229910052736 halogen Inorganic materials 0.000 claims 15
- 150000002367 halogens Chemical class 0.000 claims 15
- 125000004093 cyano group Chemical group *C#N 0.000 claims 14
- 125000000623 heterocyclic group Chemical group 0.000 claims 13
- 125000001072 heteroaryl group Chemical group 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 12
- 208000009956 adenocarcinoma Diseases 0.000 claims 11
- 125000004404 heteroalkyl group Chemical group 0.000 claims 11
- 125000001188 haloalkyl group Chemical group 0.000 claims 10
- 150000002431 hydrogen Chemical class 0.000 claims 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims 9
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- 206010025323 Lymphomas Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 7
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 6
- 229910052805 deuterium Inorganic materials 0.000 claims 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims 6
- 201000004458 Myoma Diseases 0.000 claims 5
- 206010039491 Sarcoma Diseases 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 239000003085 diluting agent Substances 0.000 claims 5
- 239000003937 drug carrier Substances 0.000 claims 5
- 206010016629 fibroma Diseases 0.000 claims 5
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 4
- 206010061692 Benign muscle neoplasm Diseases 0.000 claims 4
- 206010024612 Lipoma Diseases 0.000 claims 4
- 201000011066 hemangioma Diseases 0.000 claims 4
- 230000036244 malformation Effects 0.000 claims 4
- 125000004043 oxo group Chemical group O=* 0.000 claims 4
- 206010014733 Endometrial cancer Diseases 0.000 claims 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 3
- 201000008808 Fibrosarcoma Diseases 0.000 claims 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims 3
- 210000004379 membrane Anatomy 0.000 claims 3
- 239000012528 membrane Substances 0.000 claims 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 3
- 125000004193 piperazinyl group Chemical group 0.000 claims 3
- 102200006538 rs121913530 Human genes 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 3
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 208000007054 Medullary Carcinoma Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 208000026900 bile duct neoplasm Diseases 0.000 claims 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 210000002919 epithelial cell Anatomy 0.000 claims 2
- 230000001605 fetal effect Effects 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 208000010485 smooth muscle tumor Diseases 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 1
- QNRATNLHPGXHMA-XZHTYLCXSA-N (r)-(6-ethoxyquinolin-4-yl)-[(2s,4s,5r)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]methanol;hydrochloride Chemical compound Cl.C([C@H]([C@H](C1)CC)C2)CN1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OCC)C=C21 QNRATNLHPGXHMA-XZHTYLCXSA-N 0.000 claims 1
- 125000005962 1,4-oxazepanyl group Chemical group 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000003200 Adenoma Diseases 0.000 claims 1
- 206010001233 Adenoma benign Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 206010073106 Bone giant cell tumour malignant Diseases 0.000 claims 1
- 206010006417 Bronchial carcinoma Diseases 0.000 claims 1
- 235000002566 Capsicum Nutrition 0.000 claims 1
- 240000008574 Capsicum frutescens Species 0.000 claims 1
- 208000009458 Carcinoma in Situ Diseases 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 206010048832 Colon adenoma Diseases 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 208000000471 Dysplastic Nevus Syndrome Diseases 0.000 claims 1
- 206010062805 Dysplastic naevus Diseases 0.000 claims 1
- 241000483002 Euproctis similis Species 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 208000007659 Fibroadenoma Diseases 0.000 claims 1
- 208000007569 Giant Cell Tumors Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 201000005409 Gliomatosis cerebri Diseases 0.000 claims 1
- 206010018404 Glucagonoma Diseases 0.000 claims 1
- 206010018691 Granuloma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- 206010023509 Kyphosis Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 claims 1
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 201000004404 Neurofibroma Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 201000010133 Oligodendroglioma Diseases 0.000 claims 1
- 208000000035 Osteochondroma Diseases 0.000 claims 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims 1
- 235000011613 Pinus brutia Nutrition 0.000 claims 1
- 241000018646 Pinus brutia Species 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 235000019892 Stellar Nutrition 0.000 claims 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 210000004100 adrenal gland Anatomy 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 210000000013 bile duct Anatomy 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 201000003149 breast fibroadenoma Diseases 0.000 claims 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 claims 1
- 201000002143 bronchus adenoma Diseases 0.000 claims 1
- 239000001390 capsicum minimum Substances 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 201000005217 chondroblastoma Diseases 0.000 claims 1
- 210000004252 chorionic villi Anatomy 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000009060 clear cell adenocarcinoma Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 125000004990 dihydroxyalkyl group Chemical group 0.000 claims 1
- 235000013399 edible fruits Nutrition 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 208000037828 epithelial carcinoma Diseases 0.000 claims 1
- 208000010932 epithelial neoplasm Diseases 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 230000003325 follicular Effects 0.000 claims 1
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 claims 1
- 201000000052 gastrinoma Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 210000003494 hepatocyte Anatomy 0.000 claims 1
- 230000001096 hypoplastic effect Effects 0.000 claims 1
- 201000004933 in situ carcinoma Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 206010022498 insulinoma Diseases 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 210000001117 keloid Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 206010024627 liposarcoma Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 201000004593 malignant giant cell tumor Diseases 0.000 claims 1
- 235000013372 meat Nutrition 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 208000025113 myeloid leukemia Diseases 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 201000004662 neurofibroma of spinal cord Diseases 0.000 claims 1
- 208000004649 neutrophil actin dysfunction Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000008798 osteoma Diseases 0.000 claims 1
- 210000003101 oviduct Anatomy 0.000 claims 1
- 125000003566 oxetanyl group Chemical group 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 208000021255 pancreatic insulinoma Diseases 0.000 claims 1
- 201000010198 papillary carcinoma Diseases 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000004929 pyrrolidonyl group Chemical group N1(C(CCC1)=O)* 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 125000003003 spiro group Chemical group 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 210000004085 squamous epithelial cell Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 210000002536 stromal cell Anatomy 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 208000022271 tubular adenoma Diseases 0.000 claims 1
- 210000001635 urinary tract Anatomy 0.000 claims 1
- 210000001215 vagina Anatomy 0.000 claims 1
- 208000009540 villous adenoma Diseases 0.000 claims 1
- 0 CN1C*CCC1 Chemical compound CN1C*CCC1 0.000 description 4
- AVFZOVWCLRSYKC-UHFFFAOYSA-N CN1CCCC1 Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 2
- DMTBYMLDOZTFNH-UHFFFAOYSA-N C(C1=CCCC=C1)N1CCCC1 Chemical compound C(C1=CCCC=C1)N1CCCC1 DMTBYMLDOZTFNH-UHFFFAOYSA-N 0.000 description 1
- ZPUPZCHSZPHARG-UHFFFAOYSA-N COc1nc(CN(CC2)c3c4c(Br)cccc4ccn3)c2c(N(CC2)CCN2C(C(F)=C)=O)n1 Chemical compound COc1nc(CN(CC2)c3c4c(Br)cccc4ccn3)c2c(N(CC2)CCN2C(C(F)=C)=O)n1 ZPUPZCHSZPHARG-UHFFFAOYSA-N 0.000 description 1
- ALXGHTGDCLDMSE-SFHVURJKSA-N COc1nc(CN(CC2)c3cccc4ccnc(Cl)c34)c2c(N(CC2)C[C@H](CC#N)N2C(C(F)=C)=O)n1 Chemical compound COc1nc(CN(CC2)c3cccc4ccnc(Cl)c34)c2c(N(CC2)C[C@H](CC#N)N2C(C(F)=C)=O)n1 ALXGHTGDCLDMSE-SFHVURJKSA-N 0.000 description 1
- CDDGNGVFPQRJJM-UHFFFAOYSA-N FC1CNCC1 Chemical compound FC1CNCC1 CDDGNGVFPQRJJM-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762586775P | 2017-11-15 | 2017-11-15 | |
| US62/586,775 | 2017-11-15 | ||
| PCT/US2018/061060 WO2019099524A1 (en) | 2017-11-15 | 2018-11-14 | Kras g12c inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021502993A JP2021502993A (ja) | 2021-02-04 |
| JP2021502993A5 true JP2021502993A5 (https=) | 2021-12-23 |
| JP7322019B2 JP7322019B2 (ja) | 2023-08-07 |
Family
ID=66431793
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020526612A Active JP7322019B2 (ja) | 2017-11-15 | 2018-11-14 | Ｋｒａｓ ｇ１２ｃ阻害剤 |
| JP2021526287A Active JP7346565B2 (ja) | 2017-11-15 | 2019-05-14 | Ｋｒａｓ ｇ１２ｃ阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021526287A Active JP7346565B2 (ja) | 2017-11-15 | 2019-05-14 | Ｋｒａｓ ｇ１２ｃ阻害剤 |
Country Status (34)
| Country | Link |
|---|---|
| US (4) | US10689377B2 (https=) |
| EP (3) | EP3710439B1 (https=) |
| JP (2) | JP7322019B2 (https=) |
| KR (1) | KR102861303B1 (https=) |
| CN (2) | CN111989321B (https=) |
| AU (1) | AU2018369759B2 (https=) |
| BR (1) | BR112020009818A2 (https=) |
| CA (1) | CA3082579A1 (https=) |
| CL (1) | CL2020001271A1 (https=) |
| CO (1) | CO2020007244A2 (https=) |
| CY (2) | CY1125974T1 (https=) |
| DK (1) | DK3710439T3 (https=) |
| EA (1) | EA202091186A1 (https=) |
| ES (2) | ES2944547T3 (https=) |
| FI (2) | FI3710439T3 (https=) |
| FR (1) | FR24C1026I2 (https=) |
| HR (1) | HRP20230377T1 (https=) |
| HU (2) | HUE061599T2 (https=) |
| IL (1) | IL274601B2 (https=) |
| LT (2) | LT3710439T (https=) |
| MX (1) | MX2020005063A (https=) |
| MY (1) | MY200356A (https=) |
| NL (1) | NL301279I2 (https=) |
| PH (1) | PH12020550622A1 (https=) |
| PL (1) | PL3710439T3 (https=) |
| PT (1) | PT3710439T (https=) |
| RS (1) | RS64182B1 (https=) |
| SA (1) | SA520411982B1 (https=) |
| SG (1) | SG11202004427TA (https=) |
| SI (1) | SI3710439T1 (https=) |
| TW (1) | TWI809005B (https=) |
| UA (1) | UA125802C2 (https=) |
| WO (2) | WO2019099524A1 (https=) |
| ZA (1) | ZA202002105B (https=) |
Families Citing this family (217)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7039489B2 (ja) * | 2016-05-18 | 2022-03-22 | ミラティ セラピューティクス， インコーポレイテッド | Ｋｒａｓ ｇ１２ｃ阻害剤 |
| HRP20230377T1 (hr) * | 2017-11-15 | 2023-06-23 | Mirati Therapeutics, Inc. | Inhibitori mutacije kras g12c |
| WO2019213516A1 (en) * | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| US11932633B2 (en) | 2018-05-07 | 2024-03-19 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
| TW202012415A (zh) | 2018-05-08 | 2020-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
| US20210230170A1 (en) * | 2018-08-31 | 2021-07-29 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| WO2020055761A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| SMT202500028T1 (it) | 2018-09-10 | 2025-03-12 | Mirati Therapeutics Inc | Terapie combinate |
| CA3112043A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| JP2022500385A (ja) | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス， インコーポレイテッド | 組み合わせ療法 |
| RS66727B1 (sr) | 2018-09-10 | 2025-05-30 | Mirati Therapeutics Inc | Kombinacija dasatiniba i adagrasiba za primenu u lečenju nesitnoćelijskog kancera pluća |
| WO2020085504A1 (ja) | 2018-10-26 | 2020-04-30 | 大鵬薬品工業株式会社 | 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法 |
| PT3735299T (pt) | 2018-11-09 | 2024-11-25 | Hoffmann La Roche | Compostos de anéis fundidos |
| CN113164418A (zh) | 2018-12-05 | 2021-07-23 | 米拉蒂治疗股份有限公司 | 组合疗法 |
| WO2020146613A1 (en) | 2019-01-10 | 2020-07-16 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| WO2020165732A1 (en) | 2019-02-12 | 2020-08-20 | Novartis Ag | Pharmaceutical combination comprising tno155 and a krasg12c inhibitor |
| ES3010507T3 (en) | 2019-03-05 | 2025-04-03 | Astrazeneca Ab | Fused tricyclic compounds useful as anticancer agents |
| WO2020238791A1 (zh) * | 2019-05-24 | 2020-12-03 | 江苏恒瑞医药股份有限公司 | 氢化吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用 |
| KR20220027879A (ko) * | 2019-05-29 | 2022-03-08 | 상하이 한서 바이오메디컬 컴퍼니 리미티드 | 질소 함유 헤테로사이클릭 유도체의 조절제, 이의 제조방법 및 용도 |
| CN112047939B (zh) * | 2019-06-06 | 2023-05-02 | 江苏先声药业有限公司 | 一种具有抗肿瘤活性的四氢吡啶并嘧啶类化合物 |
| CN112300153B (zh) * | 2019-07-26 | 2023-06-13 | 博瑞生物医药（苏州）股份有限公司 | 一种杂环化合物、药物组合物和用途 |
| MX2022001421A (es) * | 2019-08-02 | 2022-06-08 | Shanghai Jemincare Pharmaceuticals Co Ltd | Compuesto tetracíclico, método de preparación y uso del mismo. |
| TWI752580B (zh) * | 2019-08-07 | 2022-01-11 | 大陸商北京加科思新藥研發有限公司 | Kras突變蛋白抑制劑 |
| CN112390788A (zh) * | 2019-08-13 | 2021-02-23 | 苏州闻天医药科技有限公司 | 一种用于抑制krasg12c突变蛋白的化合物及其制备方法和用途 |
| CN112390797A (zh) * | 2019-08-15 | 2021-02-23 | 微境生物医药科技(上海)有限公司 | 新型螺环类K-Ras G12C抑制剂 |
| WO2021043322A1 (zh) * | 2019-09-06 | 2021-03-11 | 正大天晴药业集团南京顺欣制药有限公司 | 氮杂环庚烷并嘧啶类衍生物及其医药用途 |
| EP4031542B1 (en) * | 2019-09-18 | 2025-10-15 | Merck Sharp & Dohme LLC | Small molecule inhibitors of kras g12c mutant |
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| CN114761012B (zh) * | 2019-09-24 | 2025-03-21 | 米拉蒂治疗股份有限公司 | 组合疗法 |
| US20210094919A1 (en) * | 2019-09-25 | 2021-04-01 | Jacobio Pharmaceuticals Co., Ltd. | Kras mutant protein inhibitors |
| US12478624B2 (en) | 2019-10-02 | 2025-11-25 | Tolremo Therapeutics Ag | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer |
| CN114555586B (zh) * | 2019-10-10 | 2023-06-23 | 信达生物制药(苏州)有限公司 | Krasg12c蛋白抑制剂及其制备方法和用途 |
| CN112694475B (zh) * | 2019-10-23 | 2025-09-23 | 苏州泽璟生物制药股份有限公司 | 环烷基类和杂环烷基类抑制剂及其制备方法和应用 |
| CN114867726B (zh) | 2019-10-28 | 2023-11-28 | 默沙东有限责任公司 | Kras g12c突变体的小分子抑制剂 |
| PT4053118T (pt) * | 2019-10-30 | 2024-12-05 | Genfleet Therapeutics Shanghai Inc | Composto cíclico fundido heterocíclico substituído, método de preparação deste e utilização farmacêutica deste |
| CN120699039A (zh) | 2019-11-04 | 2025-09-26 | 锐新医药公司 | Ras抑制剂 |
| WO2021088458A1 (en) * | 2019-11-04 | 2021-05-14 | Jacobio Pharmaceuticals Co., Ltd. | Kras mutant protein inhibitor |
| WO2021091956A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| MX2022005359A (es) | 2019-11-04 | 2022-06-02 | Revolution Medicines Inc | Inhibidores de ras. |
| CN112778301A (zh) * | 2019-11-07 | 2021-05-11 | 苏州泽璟生物制药股份有限公司 | 四氢吡啶并嘧啶类抑制剂及其制备方法和应用 |
| CN112824410A (zh) * | 2019-11-21 | 2021-05-21 | 苏州泽璟生物制药股份有限公司 | 氮杂七元环类抑制剂及其制备方法和应用 |
| CN114901286B (zh) | 2019-11-27 | 2024-05-10 | 特普医药公司 | 涉及二芳基巨环化合物的组合疗法 |
| EP4065231A1 (en) | 2019-11-27 | 2022-10-05 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| WO2021106231A1 (en) * | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
| US12479834B2 (en) | 2019-11-29 | 2025-11-25 | Taiho Pharmaceutical Co., Ltd. | Phenol compound or salt thereof |
| BR112022010254A2 (pt) * | 2019-12-02 | 2022-09-06 | Shanghai Yingli Pharm Co Ltd | Composto heterocíclico contendo oxigênio representado pela fórmula i, método para preparar o composto heterocíclico contendo oxigênio, composto, composição farmacêutica e uso composto heterocíclico contendo oxigênio |
| ES2929700T3 (es) | 2019-12-11 | 2022-12-01 | Lilly Co Eli | Inhibidores de KRas g12c |
| CA3165238A1 (en) * | 2019-12-19 | 2021-06-24 | Jacobio Pharmaceuticals Co., Ltd. | Kras mutant protein inhibitors |
| CN113004269B (zh) * | 2019-12-19 | 2024-11-05 | 首药控股(北京)股份有限公司 | Kras-G12C抑制剂杂环化合物 |
| PH12022551513A1 (en) | 2019-12-20 | 2023-04-24 | Mirati Therapeutics Inc | Sos1 inhibitors |
| WO2021120890A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Pyrazolyl derivatives useful as anti-cancer agents |
| CN113045565A (zh) * | 2019-12-27 | 2021-06-29 | 微境生物医药科技(上海)有限公司 | 新型K-Ras G12C抑制剂 |
| CN112094269B (zh) * | 2020-01-01 | 2021-12-07 | 上海凌达生物医药有限公司 | 一类饱和六元环并杂环类化合物、制备方法和用途 |
| TWI770760B (zh) | 2020-01-08 | 2022-07-11 | 大陸商蘇州亞盛藥業有限公司 | 螺環四氫喹唑啉 |
| GB202001344D0 (en) | 2020-01-31 | 2020-03-18 | Redx Pharma Plc | Ras Inhibitors |
| EP4077328A4 (en) * | 2020-02-20 | 2023-11-29 | Beta Pharma, Inc. | PYRIDOPYRIMIDE DERIVATIVES AS KRAS INHIBITORS |
| TW202140450A (zh) * | 2020-02-24 | 2021-11-01 | 大陸商泰勵生物科技（上海）有限公司 | 用於癌症治療的ｋｒａｓ抑制劑 |
| WO2023205701A1 (en) | 2022-04-20 | 2023-10-26 | Kumquat Biosciences Inc. | Macrocyclic heterocycles and uses thereof |
| KR102822517B1 (ko) * | 2020-03-12 | 2025-06-19 | 디3 바이오 (우씨) 컴퍼니, 리미티드 | 피리미도헤테로사이클릭 화합물 및 이의 응용 |
| US20230203055A1 (en) * | 2020-04-28 | 2023-06-29 | Betta Pharmaceuticals Co., Ltd | Fused ring compound and application thereof in medicine |
| CN116194456B (zh) * | 2020-04-30 | 2025-08-29 | 上海科州药物股份有限公司 | 作为kras抑制剂的杂环化合物的制备及其应用方法 |
| US11739102B2 (en) | 2020-05-13 | 2023-08-29 | Incyte Corporation | Fused pyrimidine compounds as KRAS inhibitors |
| CN113666923A (zh) * | 2020-05-15 | 2021-11-19 | 苏州泽璟生物制药股份有限公司 | 烷氧基烷基取代杂环基类抑制剂及其制备方法和应用 |
| WO2021245055A1 (en) | 2020-06-02 | 2021-12-09 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| EP4161934A1 (en) * | 2020-06-04 | 2023-04-12 | Antengene Discovery Limited | Inhibitors of kras g12c protein and uses thereof |
| IL299131A (en) | 2020-06-18 | 2023-02-01 | Revolution Medicines Inc | Methods for delaying, preventing and treating acquired resistance to RAS inhibitors |
| EP4171570A1 (en) | 2020-06-24 | 2023-05-03 | Boehringer Ingelheim International GmbH | Anticancer combination therapy comprising a sos1 inhibitor and a kras g12c inhibitor |
| IL299344A (en) | 2020-06-25 | 2023-02-01 | Tolremo Therapeutics Ag | Combination of a cbp/p300 bromodomain inhibitor and a kras inhibitor for the treatment of cancer |
| CN113912608B (zh) * | 2020-07-10 | 2023-07-14 | 江苏恒瑞医药股份有限公司 | 嘧啶并嘧啶酮类衍生物、其制备方法及其在医药上的应用 |
| CN113980014B (zh) * | 2020-07-27 | 2023-05-12 | 江苏恒瑞医药股份有限公司 | 氢化吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用 |
| CN115956080B (zh) * | 2020-08-17 | 2025-07-11 | 贝达药业股份有限公司 | 双环化合物，包含其的组合物及其应用 |
| CN116368130A (zh) | 2020-08-28 | 2023-06-30 | 金橘生物科技公司 | 杂环化合物及其用途 |
| MX2023002248A (es) | 2020-09-03 | 2023-05-16 | Revolution Medicines Inc | Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2. |
| CN116601151A (zh) * | 2020-09-11 | 2023-08-15 | 米拉蒂治疗股份有限公司 | Kras g12c抑制剂的晶型 |
| CN116133662A (zh) | 2020-09-11 | 2023-05-16 | 南京明德新药研发有限公司 | 氮杂环丁烷取代化合物的晶型 |
| WO2022056307A1 (en) * | 2020-09-11 | 2022-03-17 | Mirati Therapeutics, Inc. | Crystalline forms of a kras g12c inhibitor |
| MX2023003060A (es) | 2020-09-15 | 2023-04-05 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer. |
| AU2021347232A1 (en) | 2020-09-23 | 2023-04-27 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| US20220112204A1 (en) * | 2020-10-14 | 2022-04-14 | Accutar Biotechnology Inc. | Substituted dihydropyranopyrimidine compounds as kras inhibitors |
| EP4232039A4 (en) * | 2020-10-23 | 2024-08-14 | Mirati Therapeutics, Inc. | METHODS OF TREATING LUNG CANCER |
| BR112023007912A2 (pt) * | 2020-10-30 | 2024-01-02 | Novartis Ag | Formas cristalinas de um composto inibidor de kras g12c |
| CN120887884A (zh) | 2020-11-06 | 2025-11-04 | 泰励生物科技（上海）有限公司 | 用于癌症治疗的KRas抑制剂 |
| EP4247807A4 (en) * | 2020-11-23 | 2024-10-16 | Merck Sharp & Dohme LLC | 6,7-DIHYDRO-PYRANO[2,3-D PYRIMIDINE AS INHIBITORS OF THE KRAS G12C MUTANT |
| CN114591319B (zh) * | 2020-12-04 | 2024-06-28 | 江苏先声药业有限公司 | 四氢吡啶并嘧啶类衍生物及其用途 |
| CN116829151A (zh) * | 2020-12-15 | 2023-09-29 | 米拉蒂治疗股份有限公司 | 氮杂喹唑啉泛KRas抑制剂 |
| WO2022132200A1 (en) * | 2020-12-15 | 2022-06-23 | Mirati Therapeutics, Inc. | Azaquinazoline pan-kras inhibitors |
| EP4262803A4 (en) | 2020-12-16 | 2025-03-12 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| CN116529249A (zh) * | 2020-12-18 | 2023-08-01 | 正大天晴药业集团股份有限公司 | 吡啶并嘧啶酮类化合物 |
| WO2022133345A1 (en) | 2020-12-18 | 2022-06-23 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| US20240115711A1 (en) | 2020-12-18 | 2024-04-11 | Amphista Therapeutics Limited | Novel Bifunctional Molecules For Targeted Protein Degradation |
| US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| TW202241414A (zh) * | 2020-12-22 | 2022-11-01 | 瑞士商諾華公司 | 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合以及ｋｒａｓ ｇ１２ｃ抑制劑用於治療癌症之用途 |
| CN114716436A (zh) * | 2021-01-04 | 2022-07-08 | 广州百霆医药科技有限公司 | Kras g12c突变抑制剂及其用途 |
| WO2022148421A1 (en) * | 2021-01-08 | 2022-07-14 | Beigene, Ltd. | Bridged compounds as kras g12d inhibitor and degrader and the use thereof |
| EP4284370A4 (en) * | 2021-01-29 | 2024-12-11 | Mirati Therapeutics, Inc. | POLYTHERAPIES |
| US20250066387A9 (en) * | 2021-02-01 | 2025-02-27 | D3 Bio (Wuxi) Co., Ltd. | Pyrimidopyran compound |
| WO2022171143A1 (zh) * | 2021-02-09 | 2022-08-18 | 南京明德新药研发有限公司 | 5,6,7,8-四氢吡啶[3,4-d]嘧啶化合物 |
| WO2022187527A1 (en) * | 2021-03-05 | 2022-09-09 | Nikang Therapeutics, Inc | Quinazoline nitrile derivatives as kras inhibitors |
| EP4308559A1 (en) | 2021-03-15 | 2024-01-24 | Novartis AG | Benzisoxazole derivatives and uses thereof |
| WO2022194192A1 (zh) * | 2021-03-18 | 2022-09-22 | 四川科伦博泰生物医药股份有限公司 | 一类杂芳环化合物、其制备方法及用途 |
| WO2022204112A1 (en) | 2021-03-22 | 2022-09-29 | Incyte Corporation | Imidazole and triazole kras inhibitors |
| CN115124524A (zh) * | 2021-03-26 | 2022-09-30 | 浙江海正药业股份有限公司 | 三环类衍生物及其制备方法和用途 |
| WO2022206724A1 (zh) * | 2021-03-30 | 2022-10-06 | 浙江海正药业股份有限公司 | 杂环类衍生物及其制备方法和用途 |
| BR112023020538A2 (pt) | 2021-04-07 | 2024-01-23 | Tolremo Therapeutics Ag | Derivados heterocíclicos, composições farmacêuticas e seus usos no tratamento ou na melhoria de câncer |
| IL307392A (en) | 2021-04-08 | 2023-12-01 | Mirati Therapeutics Inc | Combination therapies with PRMT5 inhibitors for cancer treatment |
| WO2022217042A1 (en) * | 2021-04-09 | 2022-10-13 | Ikena Oncology, Inc. | Naphthyl-substituted quinoline-4(1h)-ones and related compounds and their use in treating medical conditions |
| WO2022214594A1 (en) | 2021-04-09 | 2022-10-13 | Boehringer Ingelheim International Gmbh | Anticancer therapy |
| CN117203208A (zh) * | 2021-04-23 | 2023-12-08 | 清华大学 | 靶向活化与失活态kras g12d的抑制剂 |
| AU2022268962A1 (en) | 2021-05-05 | 2023-12-14 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
| CA3217393A1 (en) | 2021-05-05 | 2022-11-10 | Elena S. Koltun | Ras inhibitors |
| CN117337193A (zh) * | 2021-05-19 | 2024-01-02 | 基因泰克公司 | 组合疗法 |
| WO2022247760A1 (zh) * | 2021-05-22 | 2022-12-01 | 上海科州药物研发有限公司 | 作为kras抑制剂的杂环化合物，及其制备和治疗用途 |
| EP4346826A4 (en) | 2021-05-27 | 2025-04-30 | Mirati Therapeutics, Inc. | COMBINATION THERAPIES |
| WO2022250170A1 (en) * | 2021-05-28 | 2022-12-01 | Taiho Pharmaceutical Co., Ltd. | Small molecule inhibitors of kras mutated proteins |
| US20240417408A1 (en) * | 2021-05-28 | 2024-12-19 | Merck Sharp & Dohme Corp. | Small molecule inhibitors of kras g12c mutant |
| CN117500799A (zh) | 2021-06-09 | 2024-02-02 | 伊莱利利公司 | 作为kras g12d抑制剂的取代的稠合吖嗪 |
| CN113429405A (zh) * | 2021-06-10 | 2021-09-24 | 都创(上海)医药开发有限公司 | Mrtx849化合物的晶型及其制备方法和用途 |
| US20240293558A1 (en) | 2021-06-16 | 2024-09-05 | Erasca, Inc. | Kras inhibitor conjugates |
| CN117529321A (zh) * | 2021-06-18 | 2024-02-06 | 上海德琪医药科技有限公司 | Erk抑制剂和kras抑制剂的组合及其用途 |
| TW202317100A (zh) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途 |
| CN115521312A (zh) * | 2021-06-24 | 2022-12-27 | 上海希迈医药科技有限公司 | Adagrasib的固体形式及其制备方法 |
| WO2023280280A1 (zh) * | 2021-07-07 | 2023-01-12 | 微境生物医药科技(上海)有限公司 | 作为KRas G12D抑制剂的稠环化合物 |
| MX2024000357A (es) | 2021-07-07 | 2024-02-12 | Incyte Corp | Compuestos triciclicos como inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras). |
| WO2023284730A1 (en) | 2021-07-14 | 2023-01-19 | Nikang Therapeutics, Inc. | Alkylidene derivatives as kras inhibitors |
| US12600717B2 (en) | 2021-07-14 | 2026-04-14 | Incyte Corporation | Tricyclic compounds as inhibitors of KRAS |
| WO2023283933A1 (en) * | 2021-07-16 | 2023-01-19 | Silexon Biotech Co., Ltd. | Compounds useful as kras g12d inhibitors |
| CN117677398A (zh) | 2021-07-27 | 2024-03-08 | 东丽株式会社 | 用于癌的治疗和/或预防的药品 |
| CN113527294A (zh) * | 2021-08-25 | 2021-10-22 | 都创(上海)医药开发有限公司 | Mrtx849化合物的晶型及其制备方法和用途 |
| US12441742B2 (en) | 2021-08-31 | 2025-10-14 | Incyte Corporation | Naphthyridine compounds as inhibitors of KRAS |
| CA3224341A1 (en) | 2021-09-01 | 2023-03-09 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
| EP4389751A1 (en) | 2021-09-03 | 2024-06-26 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| US20240400558A1 (en) * | 2021-09-09 | 2024-12-05 | Mirati Therapeutics, Inc. | Processes and intermediates for synthesis of adagrasib |
| CN118043330A (zh) * | 2021-09-29 | 2024-05-14 | 海南先声再明医药股份有限公司 | Kras g12d抑制剂化合物及其制备方法和应用 |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| WO2023066371A1 (zh) | 2021-10-22 | 2023-04-27 | 江苏恒瑞医药股份有限公司 | 含氮的四环化合物、其制备方法及其在医药上的应用 |
| TW202334138A (zh) | 2021-11-05 | 2023-09-01 | 美商新領域醫藥公司 | 癌症治療方法 |
| EP4436957A1 (en) | 2021-11-24 | 2024-10-02 | Genentech, Inc. | Therapeutic indazole compounds and methods of use in the treatment of cancer |
| TW202340212A (zh) | 2021-11-24 | 2023-10-16 | 美商建南德克公司 | 治療性化合物及其使用方法 |
| WO2023099624A1 (en) | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| JP7779584B2 (ja) * | 2021-12-02 | 2025-12-03 | 上海和誉生物医薬科技有限公司 | Ｋｒａｓ阻害剤とその製造及び薬学における応用 |
| TW202340214A (zh) | 2021-12-17 | 2023-10-16 | 美商健臻公司 | 做為shp2抑制劑之吡唑并吡𠯤化合物 |
| EP4452964A1 (en) | 2021-12-22 | 2024-10-30 | Boehringer Ingelheim International GmbH | Heteroaromatic compounds for the treatment of cancer |
| CN118434422A (zh) | 2021-12-28 | 2024-08-02 | 阿斯利康(英国)有限公司 | 抗体-药物缀合物和rasg12c抑制剂的组合 |
| CN114409653A (zh) * | 2021-12-31 | 2022-04-29 | 苏州闻天医药科技有限公司 | 一种桥环并嘧啶并环类化合物及其用途 |
| CN118556063A (zh) * | 2022-01-21 | 2024-08-27 | 上海湃隆生物科技有限公司 | 杂环类化合物、药物组合物及其应用 |
| EP4476202A1 (en) * | 2022-02-11 | 2024-12-18 | Wave Life Sciences Ltd. | Stereoselective technologies for chiral compounds |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| CN119136806A (zh) | 2022-03-08 | 2024-12-13 | 锐新医药公司 | 用于治疗免疫难治性肺癌的方法 |
| KR20240163107A (ko) | 2022-03-11 | 2024-11-18 | 컴쿼트 바이오사이언시즈 인크. | 헤테로환 화합물 및 이의 용도 |
| JP7676677B2 (ja) | 2022-03-25 | 2025-05-14 | イーライ リリー アンド カンパニー | Ｋｒａｓ阻害剤 |
| CN116854642A (zh) * | 2022-03-26 | 2023-10-10 | 重庆博腾制药科技股份有限公司 | 一种（s）-2-哌嗪乙腈及其盐酸盐的制备方法 |
| US20250177406A1 (en) | 2022-03-31 | 2025-06-05 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumors |
| EP4504203A1 (en) | 2022-04-04 | 2025-02-12 | Sanofi | Therapeutic combination of kras g12c inhibitor and tead inhibitor |
| WO2023199180A1 (en) | 2022-04-11 | 2023-10-19 | Novartis Ag | Therapeutic uses of a krasg12c inhibitor |
| EP4511372A4 (en) * | 2022-04-18 | 2026-04-01 | Mirati Therapeutics Inc | PROCESSES AND INTERMEDIARIES FOR ADAGRASIB SYNTHESIS |
| CA3256645A1 (en) | 2022-05-06 | 2025-04-23 | Chugai Seiyaku Kabushiki Kaisha | CYCLIC COMPOUND HAVING A SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS |
| CN114907387B (zh) * | 2022-05-26 | 2023-11-10 | 中山大学 | 嘧啶并吡咯类kras抑制剂及其制备方法与应用 |
| CN117164580A (zh) * | 2022-05-27 | 2023-12-05 | 苏州泽璟生物制药股份有限公司 | 一种kras g12c抑制剂的制备方法及其中间体 |
| CN117164526A (zh) * | 2022-05-27 | 2023-12-05 | 苏州泽璟生物制药股份有限公司 | 2-(哌嗪-2-基)乙腈类衍生物及其制备方法和应用 |
| KR20250022140A (ko) | 2022-06-10 | 2025-02-14 | 브리스톨-마이어스 스큅 컴퍼니 | Kras 억제제로서의 테트라하이드로피리도 3,4-d 피리미딘 유도체 |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| CA3261681A1 (en) | 2022-08-05 | 2024-02-08 | Kumquat Biosciences Inc. | HETEROCYCLIC COMPOUNDS AND THEIR USES |
| EP4573095A1 (en) | 2022-08-17 | 2025-06-25 | Treeline Biosciences, Inc. | Pyridopyrimidine kras inhibitors |
| PE20251110A1 (es) | 2022-08-19 | 2025-04-22 | Mirati Therapeutics Inc | Composiciones farmaceuticas solidas de adagrasib |
| GB202212641D0 (en) | 2022-08-31 | 2022-10-12 | Jazz Pharmaceuticals Ireland Ltd | Novel compounds |
| JP2026504244A (ja) | 2022-11-09 | 2026-02-04 | レヴォリューション・メディスンズ，インコーポレイテッド | 化合物、複合体、ならびにそれらの調製方法及びそれらの使用方法 |
| WO2024112654A1 (en) | 2022-11-21 | 2024-05-30 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| CN116789609A (zh) * | 2023-03-03 | 2023-09-22 | 南京优氟医药科技有限公司 | 一种(r)-2-(哌嗪-2-基)乙腈盐酸盐的制备方法 |
| CN116768804A (zh) * | 2023-03-15 | 2023-09-19 | 南京优氟医药科技有限公司 | 一种(s)-2-(哌嗪-2-基)乙腈盐酸盐的制备方法 |
| WO2024206747A1 (en) | 2023-03-30 | 2024-10-03 | Eli Lilly And Company | Kras inhibitors |
| EP4687905A1 (en) | 2023-03-30 | 2026-02-11 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| EP4688792A1 (en) | 2023-03-31 | 2026-02-11 | Eli Lilly and Company | Kras inhibitors |
| JPWO2024209717A1 (https=) | 2023-04-06 | 2024-10-10 | ||
| CN121263418A (zh) | 2023-04-07 | 2026-01-02 | 锐新医药公司 | 大环ras抑制剂 |
| KR20260005904A (ko) | 2023-04-07 | 2026-01-12 | 레볼루션 메디슨즈, 인크. | 매크로사이클릭 ras 억제제 |
| AU2024252105A1 (en) | 2023-04-14 | 2025-10-16 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| KR20250172857A (ko) | 2023-04-14 | 2025-12-09 | 레볼루션 메디슨즈, 인크. | Ras 억제제의 결정형 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| CN121399123A (zh) * | 2023-05-04 | 2026-01-23 | 前沿药品公司 | 作为突变型kras g12c抑制剂用于治疗癌症的吡啶并[4,3-d]嘧啶衍生物 |
| CN120981456A (zh) | 2023-05-24 | 2025-11-18 | 金橘生物科技公司 | 杂环化合物及其用途 |
| TW202510886A (zh) | 2023-05-31 | 2025-03-16 | 德商百靈佳殷格翰國際股份有限公司 | 作為用於預測癌症治療反應性之生物標記之存活素 |
| WO2024248123A1 (ja) | 2023-06-02 | 2024-12-05 | 第一三共株式会社 | 抗ｈｅｒ３抗体－薬物コンジュゲートとｒａｓｇ１２ｃ阻害剤の組み合わせ |
| CN116675690B (zh) * | 2023-06-02 | 2026-03-27 | 北京康立生医药技术开发有限公司 | 一种肺癌治疗药物的制备方法 |
| CN121605110A (zh) | 2023-06-06 | 2026-03-03 | 金橘生物科技公司 | 取代杂环化合物及其用途 |
| CN116478141B (zh) * | 2023-06-20 | 2023-10-24 | 药康众拓(江苏)医药科技有限公司 | 氘代kras抑制剂药物及用途 |
| AU2024307234A1 (en) | 2023-06-30 | 2026-01-29 | Kumquat Biosciences Inc. | Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors |
| CN121866055A (zh) * | 2023-07-20 | 2026-04-14 | 米拉蒂治疗公司 | 阿达格拉西布盐的结晶形式 |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| TW202528315A (zh) | 2023-09-21 | 2025-07-16 | 美商樹線生物科學公司 | 螺環二氫哌喃并吡啶ＫＲａｓ抑制劑 |
| WO2025072457A1 (en) | 2023-09-27 | 2025-04-03 | Eli Lilly And Company | Kras inhibitors |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025085748A1 (en) | 2023-10-20 | 2025-04-24 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras proteins |
| TW202543645A (zh) | 2023-12-20 | 2025-11-16 | 德商百靈佳殷格翰國際股份有限公司 | 抗癌組合治療 |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| WO2025171055A1 (en) | 2024-02-06 | 2025-08-14 | Kumquat Biosciences Inc. | Heterocyclic conjugates and uses thereof |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025230971A1 (en) | 2024-04-30 | 2025-11-06 | Kumquat Biosciences Inc. | Macrocyclic heterocycles as anticancer agents |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025245127A1 (en) | 2024-05-21 | 2025-11-27 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| WO2025242126A1 (zh) * | 2024-05-22 | 2025-11-27 | 上海正大天晴医药科技开发有限公司 | 一种药物组合及其应用 |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026003808A1 (en) | 2024-06-28 | 2026-01-02 | Assia Chemical Industries Ltd. | Solid state form of adagrasib and process for preparation |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026035945A1 (en) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload |
| WO2026035947A1 (en) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Kras-targeting covalent-induced drug conjugates comprising a topoisomerase payload |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026059955A1 (en) | 2024-09-11 | 2026-03-19 | Eli Lilly And Company | (3-((6-(2-amino-benzo[d]thiazol-4-yl)-3-(pyrrolidin-1-yl)-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)amino)- piperidin-2-one derivatives as kras inhibitors for the treatment of cancer |
| WO2026064527A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload |
| WO2026064520A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| US12600733B2 (en) | 2024-10-01 | 2026-04-14 | Eli Lilly And Company | KRAS inhibitors |
| WO2026075942A1 (en) | 2024-10-01 | 2026-04-09 | Eli Lilly And Company | Kras inhibitors |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2432578C (en) | 2001-01-02 | 2008-04-01 | F. Hoffmann-La Roche Ag | Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists |
| WO2002088079A2 (en) | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
| US7105667B2 (en) | 2001-05-01 | 2006-09-12 | Bristol-Myers Squibb Co. | Fused heterocyclic compounds and use thereof |
| US20080051387A1 (en) | 2006-06-09 | 2008-02-28 | Yuelian Xu | Tetrahydropyrido[3,4-d]pyrimidines and related analogues |
| US9259426B2 (en) | 2006-07-20 | 2016-02-16 | Gilead Sciences, Inc. | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections |
| CA2673299C (en) | 2006-12-21 | 2016-04-12 | Sloan-Kettering Institute For Cancer Research | Pyridazinone compounds for the treatment of proliferative diseases |
| WO2008103470A2 (en) | 2007-02-21 | 2008-08-28 | Trustees Of Columbia University In The City Of New York | Oncogenic-ras-signal dependent lethal compounds |
| CN101679308B (zh) | 2007-03-14 | 2014-05-07 | 埃克塞里艾克西斯公司 | Hedgehog途径抑制剂 |
| EP2209775A1 (en) | 2007-10-09 | 2010-07-28 | UCB Pharma, S.A. | Heterobicyclic compounds as histamine h4-receptor antagonists |
| EP2278976A1 (en) | 2008-04-07 | 2011-02-02 | Gilead Sciences, Inc. | 2h-benzo[b][1,4]oxazin-3(4h)-one derivatives for use as stearoyl coa desaturase inhibitors |
| AR073354A1 (es) | 2008-07-31 | 2010-11-03 | Genentech Inc | Compuestos de pirimidina, composiciones farmaceuticas y su uso en el tratamiento del cancer. |
| WO2010120996A1 (en) | 2009-04-17 | 2010-10-21 | Wyeth Llc | 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
| EP2518064A1 (en) | 2009-12-25 | 2012-10-31 | Mochida Pharmaceutical Co., Ltd. | Novel aryl urea derivative |
| EP2519664A4 (en) | 2009-12-30 | 2014-03-12 | Avila Therapeutics Inc | LIGAND-RELATED COVALENTS MODIFYING A PROTEIN |
| EP2836482B1 (en) | 2012-04-10 | 2019-12-25 | The Regents of The University of California | Compositions and methods for treating cancer |
| WO2014011973A2 (en) | 2012-07-13 | 2014-01-16 | The Trustees Of Columbia University In The City Of New York | Quinazolinone-based oncogenic-ras-selective lethal compounds and their use |
| JP6473133B2 (ja) | 2013-03-15 | 2019-02-20 | アラクセス ファーマ エルエルシー | Ｋｒａｓｇ１２ｃの共有結合性阻害剤 |
| UY35464A (es) | 2013-03-15 | 2014-10-31 | Araxes Pharma Llc | Inhibidores covalentes de kras g12c. |
| US9745319B2 (en) | 2013-03-15 | 2017-08-29 | Araxes Pharma Llc | Irreversible covalent inhibitors of the GTPase K-Ras G12C |
| TWI659021B (zh) | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Ｋｒａｓ ｇ１２ｃ之抑制劑 |
| AU2014331794C1 (en) * | 2013-10-10 | 2019-09-12 | Araxes Pharma Llc | Inhibitors of KRAS G12C |
| MA40074A (fr) | 2014-05-30 | 2015-12-03 | Univ Columbia | Composés liant ras multivalents |
| WO2016025650A1 (en) | 2014-08-13 | 2016-02-18 | Celgene Avilomics Research, Inc. | Combinations of an erk inhibitor and a cdk4/6 inhibitor and related methods |
| JO3556B1 (ar) * | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| US10011600B2 (en) | 2014-09-25 | 2018-07-03 | Araxes Pharma Llc | Methods and compositions for inhibition of Ras |
| WO2016049565A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Compositions and methods for inhibition of ras |
| ES2826443T3 (es) | 2014-09-25 | 2021-05-18 | Araxes Pharma Llc | Inhibidores de proteínas mutantes KRAS G12C |
| US10017540B2 (en) | 2015-03-11 | 2018-07-10 | California Institute Of Technology | Cyclic peptide binder against oncogenic K-Ras |
| JP2018513853A (ja) | 2015-04-10 | 2018-05-31 | アラクセス ファーマ エルエルシー | 置換キナゾリン化合物およびその使用方法 |
| JP6789239B2 (ja) | 2015-04-15 | 2020-11-25 | アラクセス ファーマ エルエルシー | Ｋｒａｓの縮合三環系インヒビターおよびその使用の方法 |
| WO2016172692A1 (en) | 2015-04-24 | 2016-10-27 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Mutant kras inhibitors |
| BR112017023821A2 (pt) | 2015-05-06 | 2018-07-31 | Leidos Biomedical Res Inc | moduladores de k-ras |
| US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| JP6877414B2 (ja) | 2015-09-24 | 2021-05-26 | アイオニス・ファーマシューティカルズ・インコーポレイテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | Ｋｒａｓ発現のモジュレーター |
| US10647703B2 (en) | 2015-09-28 | 2020-05-12 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10882847B2 (en) | 2015-09-28 | 2021-01-05 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| WO2017058807A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| EP3356353A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2017058902A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| WO2017058915A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| EP3356354A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| JP2018533939A (ja) | 2015-10-19 | 2018-11-22 | アラクセス ファーマ エルエルシー | Ｒａｓの阻害剤をスクリーニングするための方法 |
| JP6953400B2 (ja) | 2015-10-22 | 2021-10-27 | ザ スクリプス リサーチ インスティテュート | システイン反応性プローブとその使用 |
| WO2017080980A1 (en) | 2015-11-09 | 2017-05-18 | Astrazeneca Ab | Dihydropyrrolopyrazinone derivatives useful in the treatment of cancer |
| WO2017079864A1 (en) | 2015-11-12 | 2017-05-18 | Hangzhou Yier Biotech Co., Ltd. | Treatment of cancers related to chronically active ras |
| KR20180081596A (ko) | 2015-11-16 | 2018-07-16 | 아락세스 파마 엘엘씨 | 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법 |
| WO2017100546A1 (en) | 2015-12-09 | 2017-06-15 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| JP7039489B2 (ja) | 2016-05-18 | 2022-03-22 | ミラティ セラピューティクス， インコーポレイテッド | Ｋｒａｓ ｇ１２ｃ阻害剤 |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| US10280172B2 (en) | 2016-09-29 | 2019-05-07 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| EP3523289A1 (en) | 2016-10-07 | 2019-08-14 | Araxes Pharma LLC | Heterocyclic compounds as inhibitors of ras and methods of use thereof |
| MX2019006296A (es) | 2016-11-30 | 2019-11-12 | Bantam Pharmaceutical Llc | Métodos de uso de compuestos de pirazol y pirazol sustituido y para el tratamiento de enfermedades hiperproliferativas. |
| AU2017366901B2 (en) | 2016-11-30 | 2022-09-29 | Bantam Pharmaceutical, Llc | Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases |
| BR112019012263A2 (pt) | 2016-12-15 | 2020-01-28 | The Regents Of The University Of California | composições e métodos para tratar câncer |
| WO2018119183A2 (en) | 2016-12-22 | 2018-06-28 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| JP7219218B2 (ja) | 2016-12-22 | 2023-02-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規のベンジルアミノ置換キナゾリンおよびｓｏｓ１阻害剤としての誘導体 |
| US10344026B2 (en) | 2017-01-18 | 2019-07-09 | Nantbio, Inc. | Compositions and methods of targeting mutant K-ras |
| WO2018140514A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
| EP3573954A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
| US20200385364A1 (en) | 2017-01-26 | 2020-12-10 | Araxes Pharma Llc | Fused n-heterocyclic compounds and methods of use thereof |
| WO2018140513A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
| WO2018140599A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
| CN110382482A (zh) * | 2017-01-26 | 2019-10-25 | 亚瑞克西斯制药公司 | 稠合的杂-杂二环化合物及其使用方法 |
| JOP20190186A1 (ar) | 2017-02-02 | 2019-08-01 | Astellas Pharma Inc | مركب كينازولين |
| BR112019021899A2 (pt) | 2017-04-20 | 2020-08-18 | The Regents Of The University Of California | moduladores de k-ras |
| MA50077A (fr) | 2017-09-08 | 2020-07-15 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
| US10647715B2 (en) * | 2017-11-15 | 2020-05-12 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
| HRP20230377T1 (hr) * | 2017-11-15 | 2023-06-23 | Mirati Therapeutics, Inc. | Inhibitori mutacije kras g12c |
| WO2019110751A1 (en) | 2017-12-08 | 2019-06-13 | Astrazeneca Ab | Tetracyclic compounds as inhibitors of g12c mutant ras protein, for use as anti-cancer agents |
| TW201942115A (zh) | 2018-02-01 | 2019-11-01 | 美商輝瑞股份有限公司 | 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物 |
| TW201942116A (zh) | 2018-02-09 | 2019-11-01 | 美商輝瑞股份有限公司 | 作為抗癌劑之四氫喹唑啉衍生物 |
-
2018
- 2018-11-14 HR HRP20230377TT patent/HRP20230377T1/hr unknown
- 2018-11-14 SG SG11202004427TA patent/SG11202004427TA/en unknown
- 2018-11-14 MX MX2020005063A patent/MX2020005063A/es unknown
- 2018-11-14 PT PT188794846T patent/PT3710439T/pt unknown
- 2018-11-14 LT LTEPPCT/US2018/061060T patent/LT3710439T/lt unknown
- 2018-11-14 FI FIEP18879484.6T patent/FI3710439T3/fi active
- 2018-11-14 HU HUE18879484A patent/HUE061599T2/hu unknown
- 2018-11-14 CA CA3082579A patent/CA3082579A1/en active Pending
- 2018-11-14 EA EA202091186A patent/EA202091186A1/ru unknown
- 2018-11-14 BR BR112020009818-3A patent/BR112020009818A2/pt unknown
- 2018-11-14 ES ES18879484T patent/ES2944547T3/es active Active
- 2018-11-14 UA UAA202003509A patent/UA125802C2/uk unknown
- 2018-11-14 PL PL18879484.6T patent/PL3710439T3/pl unknown
- 2018-11-14 KR KR1020207016494A patent/KR102861303B1/ko active Active
- 2018-11-14 CN CN201880086849.1A patent/CN111989321B/zh active Active
- 2018-11-14 CN CN202410549759.9A patent/CN118459460A/zh active Pending
- 2018-11-14 RS RS20230345A patent/RS64182B1/sr unknown
- 2018-11-14 SI SI201830912T patent/SI3710439T1/sl unknown
- 2018-11-14 US US16/191,190 patent/US10689377B2/en active Active
- 2018-11-14 JP JP2020526612A patent/JP7322019B2/ja active Active
- 2018-11-14 EP EP18879484.6A patent/EP3710439B1/en active Active
- 2018-11-14 IL IL274601A patent/IL274601B2/en unknown
- 2018-11-14 DK DK18879484.6T patent/DK3710439T3/da active
- 2018-11-14 WO PCT/US2018/061060 patent/WO2019099524A1/en not_active Ceased
- 2018-11-14 MY MYPI2020001151A patent/MY200356A/en unknown
- 2018-11-14 AU AU2018369759A patent/AU2018369759B2/en active Active
- 2018-11-15 TW TW107140665A patent/TWI809005B/zh active
-
2019
- 2019-05-14 JP JP2021526287A patent/JP7346565B2/ja active Active
- 2019-05-14 ES ES19886028T patent/ES3009544T3/es active Active
- 2019-05-14 EP EP19886028.0A patent/EP3880208B1/en active Active
- 2019-05-14 WO PCT/US2019/032249 patent/WO2020101736A1/en not_active Ceased
- 2019-05-14 EP EP24206860.9A patent/EP4501932A3/en active Pending
-
2020
- 2020-05-04 ZA ZA2020/02105A patent/ZA202002105B/en unknown
- 2020-05-06 US US16/868,258 patent/US20200262837A1/en not_active Abandoned
- 2020-05-13 PH PH12020550622A patent/PH12020550622A1/en unknown
- 2020-05-13 CL CL2020001271A patent/CL2020001271A1/es unknown
- 2020-05-15 SA SA520411982A patent/SA520411982B1/ar unknown
- 2020-06-12 CO CONC2020/0007244A patent/CO2020007244A2/es unknown
-
2022
- 2022-10-21 US US18/048,834 patent/US20230373999A1/en not_active Abandoned
-
2023
- 2023-05-10 CY CY20231100226T patent/CY1125974T1/el unknown
- 2023-08-04 US US18/230,580 patent/US20240101553A1/en active Pending
-
2024
- 2024-06-10 FI FIC20240021C patent/FIC20240021I1/fi unknown
- 2024-06-10 NL NL301279C patent/NL301279I2/nl unknown
- 2024-06-11 HU HUS2400019C patent/HUS2400019I1/hu unknown
- 2024-06-11 LT LTPA2024517C patent/LTC3710439I2/lt unknown
- 2024-06-13 FR FR24C1026C patent/FR24C1026I2/fr active Active
- 2024-06-13 CY CY2024020C patent/CY2024020I2/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021502993A5 (https=) | ||
| KR101937501B1 (ko) | 치환된 2,3-디히드로이미다조[1,2-ｃ]퀴나졸린 염 | |
| JP6165314B2 (ja) | 抗癌活性及び抗増殖活性を呈する２−アミノピリミジン−６−オン及び類似体 | |
| CN101229164B (zh) | 含氮杂吲哚氧代乙酰哌嗪衍生物的药物制剂 | |
| CN103429591A (zh) | 在治疗过度增殖性病症中用作mps-1和tkk抑制剂的6-取代的咪唑并吡嗪 | |
| CN104411701A (zh) | 作为Bub1抑制剂的用于治疗癌症的取代的环烯并吡唑 | |
| EA022527B1 (ru) | 2-ЗАМЕЩЕННЫЕ-8-АЛКИЛ-7-ОКСО-7,8-ДИГИДРОПИРИДО[2,3-d]ПИРИМИДИН-6-КАРБОНИТРИЛЫ И ИХ ПРИМЕНЕНИЕ | |
| JP2021513996A5 (https=) | ||
| HK1214169A1 (zh) | 用於治疗癌症的瑞戈非尼和乙酰水杨酸的组合 | |
| KR20170087966A (ko) | Ｃ－ｍｅｔ 조절제를 사용하는 방법 | |
| JP2003522163A5 (https=) | ||
| JP2019505529A5 (https=) | ||
| JP2020506244A5 (https=) | ||
| JP2020520957A5 (https=) | ||
| JP2020507625A5 (https=) | ||
| CN108239074B (zh) | 喹唑啉类化合物及其制备方法、用途和药物组合物 | |
| JP6588341B2 (ja) | 転移抑制活性を有するリン含有糖アナログ複素環 | |
| CN103864764A (zh) | 吲唑取代的嘧啶胺衍生物、其制备方法和用途 | |
| CN113214230A (zh) | 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用 | |
| CN105884680B (zh) | 吡非尼酮衍生物及其制备方法与用途 | |
| CN114786674A (zh) | Ahr抑制剂和pd1抑制剂抗体的组合及其在癌症治疗中的用途 | |
| RU2712169C2 (ru) | Новые полиморфные формы икотиниба фосфата и их применения | |
| MX2015000797A (es) | Uso de inhibidores de vegfr-3 para tratar carcinoma hepatocelular. | |
| WO2014048377A1 (zh) | 治疗肿瘤的组合药物及其应用 | |
| KR20050038632A (ko) | 양성 및 악성 종양 질환의 치료를 위한 디스오라졸 및 이의유도체를 함유하는 의약 |